Review Article
Emerging Pharmacotherapies for Diabetic Macular Edema
Table 4
Selected Systemic Agents in Treatment of Diabetic Macular Edema.
| Agent (# patients) | Main Outcomes | Reference |
| Ruboxistaurin (686) | Did not meet primary outcome measure at 30 months | [102] | Fenofibrate (9795) | Favorable outcomes versus placebo at average of 5 years | [104] | Rosiglitazone (30) | Some evidence of efficacy at 3 months, but also may worsen DME in some patients | [107] |
|
|